Effect of lactuside B on the expression of bcl-2 and bax mRNA and their protein in rats' cerebral cortex after cerebral ischemia-reperfusion injury.
- Author:
Sheng-ying LI
1
;
Juan SUN
;
Bing-xuan NIU
;
Fu-lin YAN
;
He-qin ZHAN
Author Information
1. School of Pharmacy, Xinxiang Medical University, Xinxiang 453003, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Apoptosis;
drug effects;
Asteraceae;
chemistry;
Brain Ischemia;
metabolism;
pathology;
Cerebral Cortex;
metabolism;
pathology;
Dose-Response Relationship, Drug;
Glucosides;
administration & dosage;
isolation & purification;
pharmacology;
Male;
Neurons;
drug effects;
pathology;
Plants, Medicinal;
chemistry;
Proto-Oncogene Proteins c-bcl-2;
genetics;
metabolism;
RNA, Messenger;
metabolism;
Random Allocation;
Rats;
Rats, Sprague-Dawley;
Reperfusion Injury;
metabolism;
pathology;
Rhizome;
chemistry;
Vasodilator Agents;
administration & dosage;
isolation & purification;
pharmacology;
bcl-2-Associated X Protein;
genetics;
metabolism
- From:
Acta Pharmaceutica Sinica
2011;46(11):1314-1320
- CountryChina
- Language:Chinese
-
Abstract:
This study is to investigate the effect of the major chemical composition in rhizome of Pterocypsela elata, lactuside B, on expression of bcl-2, bax mRNA and their protein in rats' cerebral cortex after cerebral ischemia-reperfusion injury. First, middle cerebral artery ischemia-reperfusion injury model was established, and each group was treated with the corresponding medicines. Animals were separately sacrificed at 24 h and 72 h. The brain infarct volumes were detected by TTC dye, bcl-2 and bax mRNA expression was checked by RT-PCR, and the proteins of bcl-2 and bax were explored by two-step immunohistochemistry in cerebral cortex of rats. Lactuside B can reduce brain infarct volume of cerebral cortex of rats, increase the expression of bcl-2 mRNA and decrease that of bax mRNA. Moreover, the ratio of bcl-2 to bax mRNA is higher in 12.5 and 25 mg kg(-1) dose group, respectively, which is significantly different from that of model group (P < 0.05 or P < 0.01). Generally, either 12.5 or 25 mg kg(-1) dose group is better than positive control medicine nimodipine (P < 0.05 or P < 0.01). In addition, the expression of bcl-2 and bax protein is consistent with their gene expression. Infarct volume and the ratio of bcl-2 to bax mRNA expression are significantly different (P < 0.05 or P < 0.01) between 72 h and 24 h group. The results demonstrated that lactuside B could play a good role in resisting cerebral ischemia by upregulating the expression of bcl-2 mRNA and protein and downregulating that of bax mRNA and protein.
